Trafficking dynamics of VEGFR1, VEGFR2, and NRP1 in human endothelial cells

被引:4
|
作者
Sarabipour, Sarvenaz [1 ,2 ]
Kinghorn, Karina [3 ,4 ]
Quigley, Kaitlyn M. [4 ]
Kovacs-Kasa, Anita [5 ,6 ]
Annex, Brian H. [5 ,6 ]
Bautch, Victoria L. [3 ,4 ,7 ]
Mac Gabhann, Feilim [1 ,2 ]
机构
[1] Johns Hopkins Univ, Inst Computat Med, Baltimore, MD 21218 USA
[2] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA
[3] Univ N Carolina, Curriculum Cell Biol & Physiol, Chapel Hill, NC USA
[4] Univ N Carolina, Dept Biol, Chapel Hill, NC USA
[5] Augusta Univ, Vasc Biol Ctr, Med Coll Georgia, Augusta, GA USA
[6] Augusta Univ, Dept Med, Med Coll Georgia, Augusta, GA USA
[7] Univ N Carolina, McAllister Heart Inst, Chapel Hill, NC USA
关键词
GROWTH-FACTOR; THERAPEUTIC ANGIOGENESIS; RECEPTOR; ENDOSOME; DOMAIN; NEUROPILIN-1; MECHANISMS; VESICLES; PATHWAY; MODEL;
D O I
10.1371/journal.pcbi.1011798
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The vascular endothelial growth factor (VEGF) family of cytokines are key drivers of blood vessel growth and remodeling. These ligands act via multiple VEGF receptors (VEGFR) and co-receptors such as Neuropilin (NRP) expressed on endothelial cells. These membrane-associated receptors are not solely expressed on the cell surface, they move between the surface and intracellular locations, where they can function differently. The location of the receptor alters its ability to 'see' (access and bind to) its ligands, which regulates receptor activation; location also alters receptor exposure to subcellularly localized phosphatases, which regulates its deactivation. Thus, receptors in different subcellular locations initiate different signaling, both in terms of quantity and quality. Similarly, the local levels of co-expression of other receptors alters competition for ligands. Subcellular localization is controlled by intracellular trafficking processes, which thus control VEGFR activity; therefore, to understand VEGFR activity, we must understand receptor trafficking. Here, for the first time, we simultaneously quantify the trafficking of VEGFR1, VEGFR2, and NRP1 on the same cells-specifically human umbilical vein endothelial cells (HUVECs). We build a computational model describing the expression, interaction, and trafficking of these receptors, and use it to simulate cell culture experiments. We use new quantitative experimental data to parameterize the model, which then provides mechanistic insight into the trafficking and localization of this receptor network. We show that VEGFR2 and NRP1 trafficking is not the same on HUVECs as on non-human ECs; and we show that VEGFR1 trafficking is not the same as VEGFR2 trafficking, but rather is faster in both internalization and recycling. As a consequence, the VEGF receptors are not evenly distributed between the cell surface and intracellular locations, with a very low percentage of VEGFR1 being on the cell surface, and high levels of NRP1 on the cell surface. Our findings have implications both for the sensing of extracellular ligands and for the composition of signaling complexes at the cell surface versus inside the cell. Receptors and their ligands are at the heart of cell-to-cell signaling, but can only interact if they are in the same place at the same time. This is controlled in part by expression-only if a cell expresses a receptor can the cell perceive and respond to that ligand. But it is also controlled in part by where in the cell that receptor is. If the receptor is on the cell surface, it may be able to bind extracellular ligands. If inside the cell, e.g. on endosomal vesicles, it may not. Similarly, the intracellular portions of receptors at the cell surface and inside the cell are exposed to different local environments and can initiate different signaling pathways. Therefore, understanding receptor localization and trafficking (how the receptors move within the cell) is an important starting point for understanding receptor function. Here, we use mechanistic computational modeling and quantitative experimental data to define the localization and trafficking of the VEGF receptors, which are key drivers of blood vessel growth and remodeling. We show that these receptors each has different trafficking and patterns of localization, which has significant implications for the differential responses of these receptors to extracellular ligands.
引用
收藏
页数:28
相关论文
共 50 条
  • [41] Potential inhibitors of VEGFR1, VEGFR2, and VEGFR3 developed through Deep Learning for the treatment of Cervical Cancer
    Nayarisseri, Anuraj
    Abdalla, Mohnad
    Joshi, Isha
    Yadav, Manasi
    Bhrdwaj, Anushka
    Chopra, Ishita
    Khan, Arshiya
    Saxena, Arshiya
    Sharma, Khushboo
    Panicker, Aravind
    Panwar, Umesh
    Mendonca Junior, Francisco Jaime Bezerra
    Singh, Sanjeev Kumar
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [42] VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2
    Z Zhang
    K G Neiva
    M W Lingen
    L M Ellis
    J E Nör
    Cell Death & Differentiation, 2010, 17 : 499 - 512
  • [43] Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma
    Masatoshi Jinnin
    Damian Medici
    Lucy Park
    Nisha Limaye
    Yanqiu Liu
    Elisa Boscolo
    Joyce Bischoff
    Miikka Vikkula
    Eileen Boye
    Bjorn R Olsen
    Nature Medicine, 2008, 14 : 1236 - 1246
  • [44] Identification of VEGFR2 as the Histatin-1 receptor in endothelial cells
    Mateluna, Carlos
    Torres, Pedro
    Rodriguez-Pena, Marcelo
    Silva, Patricio
    Matthies, Douglas J.
    Criollo, Alfredo
    Bikker, Floris J.
    Bolscher, Jan G. M.
    Wilson, Christian A. M.
    Zapata-Torres, Gerald
    Torres, Vicente A.
    BIOCHEMICAL PHARMACOLOGY, 2022, 201
  • [45] Immunolocalization of VEGF A and Its Receptors, VEGFR1 and VEGFR2, in the Liver From Patients With Biliary Atresia
    Edom, Patricia Turnes
    Meurer, Luise
    da Silveira, Themis Reverbel
    Matte, Ursula
    dos Santos, Jorge Luiz
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2011, 19 (04) : 360 - 368
  • [46] The Expression of VEGFR1 and VEGFR2 in H-pylori Infected Intestinal Metaplasia and Gastric Cancer
    Nakajima, N.
    Nakagawa, T.
    Kunoki, N.
    Ohta, S.
    Kobayashi, S.
    Nishiyama, R.
    Akai, Y.
    Ohtani, T.
    Mitshuhiko, M.
    HELICOBACTER, 2010, 15 (04) : 322 - 322
  • [47] Microvessel density and immunohistochemical expression of angiogenic proteins VEGF, VEGFR1 and VEGFR2 in gastric adenocarcinoma
    Lampri, Evangeli
    Goussia, Ann
    Sintou-Mantela, Evdoxia
    Balasi, Eufemia
    Charchanti, Antonia
    Kamina, Sevasti
    Capizzelo, Antonio
    Tsekeris, Pericles
    Briasoulis, Evangelos
    Malamou-Mitsi, Vasiliki
    Agnantis, Niki J.
    Bai, Maria
    VIRCHOWS ARCHIV, 2007, 451 (02) : 321 - 321
  • [48] Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma
    Jinnin, Masatoshi
    Medici, Damian
    Park, Lucy
    Limaye, Nisha
    Liu, Yanqiu
    Boscolo, Elisa
    Bischoff, Joyce
    Vikkula, Miikka
    Boye, Eileen
    Olsen, Bjorn R.
    NATURE MEDICINE, 2008, 14 (11) : 1236 - 1246
  • [49] Potassium Dehydroandrograpolide Succinate Targets NRP1 Mediated VEGFR2/VE-Cadherin Signaling Pathway to Promote Endothelial Barrier Repair
    Wang, Zheng
    Wu, Xiao
    Li, Jiali
    Guo, Qiru
    Jin, Zhong
    Li, Hongfei
    Liang, Bing
    Hu, Wangming
    Xu, Huan
    Shi, Liangqin
    Yang, Lan
    Wang, Yong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [50] Real-Time Ligand Binding of Fluorescent VEGF-A Isoforms that Discriminate between VEGFR2 and NRP1 in Living Cells
    Peach, Chloe J.
    Kilpatrick, Laura E.
    Friedman-Ohana, Rachel
    Zimmerman, Kris
    Robers, Matthew B.
    Wood, Keith, V
    Woolard, Jeanette
    Hill, Stephen J.
    CELL CHEMICAL BIOLOGY, 2018, 25 (10): : 1208 - +